Tanner Shae

1 week ago | ipwatchdog.com | Tanner Shae |Eileen McDermott

“The Federal Circuit’s opinion preserves the PTAB’s invalidation of the core claims of Avago’s video streaming patent but reopens the door for Netflix to challenge four remaining dependent claims.”On Wednesday, June 18, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued an opinion affirming in part and vacating in part the Patent Trial and Appeal Board’s (PTAB) decision regarding Avago Technologies’ U.S. Patent No. 8,646,014.

1 month ago | ipwatchdog.com | Tanner Shae |Steve Brachmann

“The CAFC clarified that the proper standard asks ‘whether the inventors had a definite and permanent idea of the operative inventions’ such that a person of ordinary skill could reduce it to practice without extensive experimentation.”In a precedential opinion issued on Monday, the U.S. Court of Appeals for the Federal Circuit (CAFC) vacated and remanded a Patent Trial and Appeal Board (PTAB) decision that awarded priority to the Broad Institute in the high-profile CRISPR-Cas9 patent dispute.

1 month ago | ipwatchdog.com | Tanner Shae |Steve Brachmann

“Without stronger internal controls, clearer goals, and more accurate performance data, the agency risks perpetuating a system where patents are granted too quickly and challenged too often.”The U.S. Government Accountability Office (GAO) has issued a sharply critical report concluding that the United States Patent and Trademark Office (USPTO) has failed to effectively assess and manage its initiatives aimed at improving patent quality.

1 month ago | ipwatchdog.com | Tanner Shae |Steve Brachmann

“The Federal Circuit agreed with Avadel that the district court’s injunction unlawfully blocked protected pre-approval activities.”In a precedential decision issued May 6, 2025, the U.S. Court of Appeals for the Federal Circuit (CAFC) reversed in part and vacated in part a Delaware district court’s injunction that blocked Avadel CNS Pharmaceuticals from conducting clinical research and seeking regulatory approval for expanded uses of its once-nightly narcolepsy drug, Lumryz.